Global mRNA Vaccines Market Growth 2026-2032
The global mRNA Vaccines market size is predicted to grow from US$ 8736 million in 2025 to US$ 19649 million in 2032; it is expected to grow at a CAGR of 12.3% from 2026 to 2032.
In 2025, global mRNA vaccine production was about 1.1 billion doses with capacity near 2 billion doses per year; the average revenue per dose is USD 8, and innovator gross margins are around 62%. mRNA vaccines are biologic medicines that use messenger RNA (mRNA) molecules to instruct human cells to produce a harmless piece of a pathogen (such as a viral spike protein), which triggers an immune response without exposing the body to the actual disease. Their supply chain spans multiple specialized layers: upstream raw materials (nucleotides, enzymes, plasmid DNA templates, lipid components for lipid nanoparticles, buffers, and sterile consumables), midstream manufacturing (in-vitro transcription of mRNA, purification, lipid nanoparticle encapsulation, sterile fill-finish, and cold-chain packaging), and downstream distribution and deployment (ultra-cold storage logistics, regulatory release, healthcare delivery, and post-market pharmacovigilance). The ecosystem involves biotech innovators, contract development and manufacturing organizations (CDMOs), lipid and reagent suppliers, cold-chain logistics providers, and healthcare systems, making mRNA vaccines a highly integrated biopharmaceutical supply chain driven by rapid scalability, advanced materials, and stringent quality control.
The mRNA vaccine market is driven by pandemic preparedness policies, rapid platform scalability, and expanding applications beyond infectious diseases into oncology and rare diseases. Government funding, advance purchase agreements, and national biodefense strategies remain major demand anchors, while technological advantages such as faster development timelines, modular manufacturing, and strong IP protection support premium pricing and high margins. Growth is increasingly fueled by pipeline diversification (flu, RSV, combination vaccines, personalized cancer vaccines), improvements in lipid nanoparticle delivery and thermostability, and the build-out of regional manufacturing capacity to ensure supply security.
LP Information, Inc. (LPI) ' newest research report, the ?mRNA Vaccines Industry Forecast? looks at past sales and reviews total world mRNA Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected mRNA Vaccines sales for 2026 through 2032. With mRNA Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Vaccines industry.
This Insight Report provides a comprehensive analysis of the global mRNA Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global mRNA Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global mRNA Vaccines market?
What factors are driving mRNA Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do mRNA Vaccines market opportunities vary by end market size?
How does mRNA Vaccines break out by Type, by Application?
In 2025, global mRNA vaccine production was about 1.1 billion doses with capacity near 2 billion doses per year; the average revenue per dose is USD 8, and innovator gross margins are around 62%. mRNA vaccines are biologic medicines that use messenger RNA (mRNA) molecules to instruct human cells to produce a harmless piece of a pathogen (such as a viral spike protein), which triggers an immune response without exposing the body to the actual disease. Their supply chain spans multiple specialized layers: upstream raw materials (nucleotides, enzymes, plasmid DNA templates, lipid components for lipid nanoparticles, buffers, and sterile consumables), midstream manufacturing (in-vitro transcription of mRNA, purification, lipid nanoparticle encapsulation, sterile fill-finish, and cold-chain packaging), and downstream distribution and deployment (ultra-cold storage logistics, regulatory release, healthcare delivery, and post-market pharmacovigilance). The ecosystem involves biotech innovators, contract development and manufacturing organizations (CDMOs), lipid and reagent suppliers, cold-chain logistics providers, and healthcare systems, making mRNA vaccines a highly integrated biopharmaceutical supply chain driven by rapid scalability, advanced materials, and stringent quality control.
The mRNA vaccine market is driven by pandemic preparedness policies, rapid platform scalability, and expanding applications beyond infectious diseases into oncology and rare diseases. Government funding, advance purchase agreements, and national biodefense strategies remain major demand anchors, while technological advantages such as faster development timelines, modular manufacturing, and strong IP protection support premium pricing and high margins. Growth is increasingly fueled by pipeline diversification (flu, RSV, combination vaccines, personalized cancer vaccines), improvements in lipid nanoparticle delivery and thermostability, and the build-out of regional manufacturing capacity to ensure supply security.
LP Information, Inc. (LPI) ' newest research report, the ?mRNA Vaccines Industry Forecast? looks at past sales and reviews total world mRNA Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected mRNA Vaccines sales for 2026 through 2032. With mRNA Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Vaccines industry.
This Insight Report provides a comprehensive analysis of the global mRNA Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global mRNA Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Conventional mRNA
- Self-amplifying mRNA
- Trans-amplifying mRNA
- Circular mRNA
- Standard IVT Platform Vaccines
- Modular Platform Vaccines
- Lyophilized mRNA Vaccines
- Single-antigen Vaccines
- Multivalent Vaccines
- Personalized Vaccines
- Infectious Diseases
- Autoimmune Diseases
- Cancers
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Moderna
- CureVac
- Sanofi
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA immunotherapies
- Ethris
- Tiba Biotechnology
- Pfizer
- Arcturus Therapeutics
- Genexine
- Translate Bio
What is the 10-year outlook for the global mRNA Vaccines market?
What factors are driving mRNA Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do mRNA Vaccines market opportunities vary by end market size?
How does mRNA Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global mRNA Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for mRNA Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for mRNA Vaccines by Country/Region, 2021, 2025 & 2032
2.2 mRNA Vaccines Segment by Type
2.2.1 Conventional mRNA
2.2.2 Self-amplifying mRNA
2.2.3 Trans-amplifying mRNA
2.2.4 Circular mRNA
2.2.5 mRNA Vaccines Sales by Type
2.2.5.1 Global mRNA Vaccines Sales Market Share by Type (2021-2026)
2.2.5.2 Global mRNA Vaccines Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global mRNA Vaccines Sale Price by Type (2021-2026)
2.3 mRNA Vaccines Segment by Platform Approach
2.3.1 Standard IVT Platform Vaccines
2.3.2 Modular Platform Vaccines
2.3.3 Lyophilized mRNA Vaccines
2.3.4 mRNA Vaccines Sales by Platform Approach
2.3.4.1 Global mRNA Vaccines Sales Market Share by Platform Approach (2021-2026)
2.3.4.2 Global mRNA Vaccines Revenue and Market Share by Platform Approach (2021-2026)
2.3.4.3 Global mRNA Vaccines Sale Price by Platform Approach (2021-2026)
2.4 mRNA Vaccines Segment by Antigen Strategy
2.4.1 Single-antigen Vaccines
2.4.2 Multivalent Vaccines
2.4.3 Personalized Vaccines
2.4.4 mRNA Vaccines Sales by Antigen Strategy
2.4.4.1 Global mRNA Vaccines Sales Market Share by Antigen Strategy (2021-2026)
2.4.4.2 Global mRNA Vaccines Revenue and Market Share by Antigen Strategy (2021-2026)
2.4.4.3 Global mRNA Vaccines Sale Price by Antigen Strategy (2021-2026)
2.5 mRNA Vaccines Segment by Application
2.5.1 Infectious Diseases
2.5.2 Autoimmune Diseases
2.5.3 Cancers
2.5.4 Others
2.5.5 mRNA Vaccines Sales by Application
2.5.5.1 Global mRNA Vaccines Sale Market Share by Application (2021-2026)
2.5.5.2 Global mRNA Vaccines Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global mRNA Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global mRNA Vaccines Breakdown Data by Company
3.1.1 Global mRNA Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global mRNA Vaccines Sales Market Share by Company (2021-2026)
3.2 Global mRNA Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global mRNA Vaccines Revenue by Company (2021-2026)
3.2.2 Global mRNA Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global mRNA Vaccines Sale Price by Company
3.4 Key Manufacturers mRNA Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers mRNA Vaccines Product Location Distribution
3.4.2 Players mRNA Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MRNA VACCINES BY GEOGRAPHIC REGION
4.1 World Historic mRNA Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global mRNA Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global mRNA Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic mRNA Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global mRNA Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global mRNA Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas mRNA Vaccines Sales Growth
4.4 APAC mRNA Vaccines Sales Growth
4.5 Europe mRNA Vaccines Sales Growth
4.6 Middle East & Africa mRNA Vaccines Sales Growth
5 AMERICAS
5.1 Americas mRNA Vaccines Sales by Country
5.1.1 Americas mRNA Vaccines Sales by Country (2021-2026)
5.1.2 Americas mRNA Vaccines Revenue by Country (2021-2026)
5.2 Americas mRNA Vaccines Sales by Type (2021-2026)
5.3 Americas mRNA Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA Vaccines Sales by Region
6.1.1 APAC mRNA Vaccines Sales by Region (2021-2026)
6.1.2 APAC mRNA Vaccines Revenue by Region (2021-2026)
6.2 APAC mRNA Vaccines Sales by Type (2021-2026)
6.3 APAC mRNA Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe mRNA Vaccines by Country
7.1.1 Europe mRNA Vaccines Sales by Country (2021-2026)
7.1.2 Europe mRNA Vaccines Revenue by Country (2021-2026)
7.2 Europe mRNA Vaccines Sales by Type (2021-2026)
7.3 Europe mRNA Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa mRNA Vaccines by Country
8.1.1 Middle East & Africa mRNA Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa mRNA Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa mRNA Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa mRNA Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of mRNA Vaccines
10.3 Manufacturing Process Analysis of mRNA Vaccines
10.4 Industry Chain Structure of mRNA Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 mRNA Vaccines Distributors
11.3 mRNA Vaccines Customer
12 WORLD FORECAST REVIEW FOR MRNA VACCINES BY GEOGRAPHIC REGION
12.1 Global mRNA Vaccines Market Size Forecast by Region
12.1.1 Global mRNA Vaccines Forecast by Region (2027-2032)
12.1.2 Global mRNA Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global mRNA Vaccines Forecast by Type (2027-2032)
12.7 Global mRNA Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna mRNA Vaccines Product Portfolios and Specifications
13.1.3 Moderna mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 CureVac
13.2.1 CureVac Company Information
13.2.2 CureVac mRNA Vaccines Product Portfolios and Specifications
13.2.3 CureVac mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 CureVac Main Business Overview
13.2.5 CureVac Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi mRNA Vaccines Product Portfolios and Specifications
13.3.3 Sanofi mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 BioNTech
13.4.1 BioNTech Company Information
13.4.2 BioNTech mRNA Vaccines Product Portfolios and Specifications
13.4.3 BioNTech mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioNTech Main Business Overview
13.4.5 BioNTech Latest Developments
13.5 Sangamo Therapeutics
13.5.1 Sangamo Therapeutics Company Information
13.5.2 Sangamo Therapeutics mRNA Vaccines Product Portfolios and Specifications
13.5.3 Sangamo Therapeutics mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sangamo Therapeutics Main Business Overview
13.5.5 Sangamo Therapeutics Latest Developments
13.6 Argos Therapeutics
13.6.1 Argos Therapeutics Company Information
13.6.2 Argos Therapeutics mRNA Vaccines Product Portfolios and Specifications
13.6.3 Argos Therapeutics mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Argos Therapeutics Main Business Overview
13.6.5 Argos Therapeutics Latest Developments
13.7 In-Cell-Art
13.7.1 In-Cell-Art Company Information
13.7.2 In-Cell-Art mRNA Vaccines Product Portfolios and Specifications
13.7.3 In-Cell-Art mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 In-Cell-Art Main Business Overview
13.7.5 In-Cell-Art Latest Developments
13.8 eTheRNA immunotherapies
13.8.1 eTheRNA immunotherapies Company Information
13.8.2 eTheRNA immunotherapies mRNA Vaccines Product Portfolios and Specifications
13.8.3 eTheRNA immunotherapies mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 eTheRNA immunotherapies Main Business Overview
13.8.5 eTheRNA immunotherapies Latest Developments
13.9 Ethris
13.9.1 Ethris Company Information
13.9.2 Ethris mRNA Vaccines Product Portfolios and Specifications
13.9.3 Ethris mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Ethris Main Business Overview
13.9.5 Ethris Latest Developments
13.10 Tiba Biotechnology
13.10.1 Tiba Biotechnology Company Information
13.10.2 Tiba Biotechnology mRNA Vaccines Product Portfolios and Specifications
13.10.3 Tiba Biotechnology mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Tiba Biotechnology Main Business Overview
13.10.5 Tiba Biotechnology Latest Developments
13.11 Pfizer
13.11.1 Pfizer Company Information
13.11.2 Pfizer mRNA Vaccines Product Portfolios and Specifications
13.11.3 Pfizer mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Pfizer Main Business Overview
13.11.5 Pfizer Latest Developments
13.12 Arcturus Therapeutics
13.12.1 Arcturus Therapeutics Company Information
13.12.2 Arcturus Therapeutics mRNA Vaccines Product Portfolios and Specifications
13.12.3 Arcturus Therapeutics mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Arcturus Therapeutics Main Business Overview
13.12.5 Arcturus Therapeutics Latest Developments
13.13 Genexine
13.13.1 Genexine Company Information
13.13.2 Genexine mRNA Vaccines Product Portfolios and Specifications
13.13.3 Genexine mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Genexine Main Business Overview
13.13.5 Genexine Latest Developments
13.14 Translate Bio
13.14.1 Translate Bio Company Information
13.14.2 Translate Bio mRNA Vaccines Product Portfolios and Specifications
13.14.3 Translate Bio mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Translate Bio Main Business Overview
13.14.5 Translate Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global mRNA Vaccines Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for mRNA Vaccines by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for mRNA Vaccines by Country/Region, 2021, 2025 & 2032
2.2 mRNA Vaccines Segment by Type
2.2.1 Conventional mRNA
2.2.2 Self-amplifying mRNA
2.2.3 Trans-amplifying mRNA
2.2.4 Circular mRNA
2.2.5 mRNA Vaccines Sales by Type
2.2.5.1 Global mRNA Vaccines Sales Market Share by Type (2021-2026)
2.2.5.2 Global mRNA Vaccines Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global mRNA Vaccines Sale Price by Type (2021-2026)
2.3 mRNA Vaccines Segment by Platform Approach
2.3.1 Standard IVT Platform Vaccines
2.3.2 Modular Platform Vaccines
2.3.3 Lyophilized mRNA Vaccines
2.3.4 mRNA Vaccines Sales by Platform Approach
2.3.4.1 Global mRNA Vaccines Sales Market Share by Platform Approach (2021-2026)
2.3.4.2 Global mRNA Vaccines Revenue and Market Share by Platform Approach (2021-2026)
2.3.4.3 Global mRNA Vaccines Sale Price by Platform Approach (2021-2026)
2.4 mRNA Vaccines Segment by Antigen Strategy
2.4.1 Single-antigen Vaccines
2.4.2 Multivalent Vaccines
2.4.3 Personalized Vaccines
2.4.4 mRNA Vaccines Sales by Antigen Strategy
2.4.4.1 Global mRNA Vaccines Sales Market Share by Antigen Strategy (2021-2026)
2.4.4.2 Global mRNA Vaccines Revenue and Market Share by Antigen Strategy (2021-2026)
2.4.4.3 Global mRNA Vaccines Sale Price by Antigen Strategy (2021-2026)
2.5 mRNA Vaccines Segment by Application
2.5.1 Infectious Diseases
2.5.2 Autoimmune Diseases
2.5.3 Cancers
2.5.4 Others
2.5.5 mRNA Vaccines Sales by Application
2.5.5.1 Global mRNA Vaccines Sale Market Share by Application (2021-2026)
2.5.5.2 Global mRNA Vaccines Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global mRNA Vaccines Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global mRNA Vaccines Breakdown Data by Company
3.1.1 Global mRNA Vaccines Annual Sales by Company (2021-2026)
3.1.2 Global mRNA Vaccines Sales Market Share by Company (2021-2026)
3.2 Global mRNA Vaccines Annual Revenue by Company (2021-2026)
3.2.1 Global mRNA Vaccines Revenue by Company (2021-2026)
3.2.2 Global mRNA Vaccines Revenue Market Share by Company (2021-2026)
3.3 Global mRNA Vaccines Sale Price by Company
3.4 Key Manufacturers mRNA Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers mRNA Vaccines Product Location Distribution
3.4.2 Players mRNA Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MRNA VACCINES BY GEOGRAPHIC REGION
4.1 World Historic mRNA Vaccines Market Size by Geographic Region (2021-2026)
4.1.1 Global mRNA Vaccines Annual Sales by Geographic Region (2021-2026)
4.1.2 Global mRNA Vaccines Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic mRNA Vaccines Market Size by Country/Region (2021-2026)
4.2.1 Global mRNA Vaccines Annual Sales by Country/Region (2021-2026)
4.2.2 Global mRNA Vaccines Annual Revenue by Country/Region (2021-2026)
4.3 Americas mRNA Vaccines Sales Growth
4.4 APAC mRNA Vaccines Sales Growth
4.5 Europe mRNA Vaccines Sales Growth
4.6 Middle East & Africa mRNA Vaccines Sales Growth
5 AMERICAS
5.1 Americas mRNA Vaccines Sales by Country
5.1.1 Americas mRNA Vaccines Sales by Country (2021-2026)
5.1.2 Americas mRNA Vaccines Revenue by Country (2021-2026)
5.2 Americas mRNA Vaccines Sales by Type (2021-2026)
5.3 Americas mRNA Vaccines Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA Vaccines Sales by Region
6.1.1 APAC mRNA Vaccines Sales by Region (2021-2026)
6.1.2 APAC mRNA Vaccines Revenue by Region (2021-2026)
6.2 APAC mRNA Vaccines Sales by Type (2021-2026)
6.3 APAC mRNA Vaccines Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe mRNA Vaccines by Country
7.1.1 Europe mRNA Vaccines Sales by Country (2021-2026)
7.1.2 Europe mRNA Vaccines Revenue by Country (2021-2026)
7.2 Europe mRNA Vaccines Sales by Type (2021-2026)
7.3 Europe mRNA Vaccines Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa mRNA Vaccines by Country
8.1.1 Middle East & Africa mRNA Vaccines Sales by Country (2021-2026)
8.1.2 Middle East & Africa mRNA Vaccines Revenue by Country (2021-2026)
8.2 Middle East & Africa mRNA Vaccines Sales by Type (2021-2026)
8.3 Middle East & Africa mRNA Vaccines Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of mRNA Vaccines
10.3 Manufacturing Process Analysis of mRNA Vaccines
10.4 Industry Chain Structure of mRNA Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 mRNA Vaccines Distributors
11.3 mRNA Vaccines Customer
12 WORLD FORECAST REVIEW FOR MRNA VACCINES BY GEOGRAPHIC REGION
12.1 Global mRNA Vaccines Market Size Forecast by Region
12.1.1 Global mRNA Vaccines Forecast by Region (2027-2032)
12.1.2 Global mRNA Vaccines Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global mRNA Vaccines Forecast by Type (2027-2032)
12.7 Global mRNA Vaccines Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Moderna
13.1.1 Moderna Company Information
13.1.2 Moderna mRNA Vaccines Product Portfolios and Specifications
13.1.3 Moderna mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Moderna Main Business Overview
13.1.5 Moderna Latest Developments
13.2 CureVac
13.2.1 CureVac Company Information
13.2.2 CureVac mRNA Vaccines Product Portfolios and Specifications
13.2.3 CureVac mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 CureVac Main Business Overview
13.2.5 CureVac Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi mRNA Vaccines Product Portfolios and Specifications
13.3.3 Sanofi mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 BioNTech
13.4.1 BioNTech Company Information
13.4.2 BioNTech mRNA Vaccines Product Portfolios and Specifications
13.4.3 BioNTech mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioNTech Main Business Overview
13.4.5 BioNTech Latest Developments
13.5 Sangamo Therapeutics
13.5.1 Sangamo Therapeutics Company Information
13.5.2 Sangamo Therapeutics mRNA Vaccines Product Portfolios and Specifications
13.5.3 Sangamo Therapeutics mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sangamo Therapeutics Main Business Overview
13.5.5 Sangamo Therapeutics Latest Developments
13.6 Argos Therapeutics
13.6.1 Argos Therapeutics Company Information
13.6.2 Argos Therapeutics mRNA Vaccines Product Portfolios and Specifications
13.6.3 Argos Therapeutics mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Argos Therapeutics Main Business Overview
13.6.5 Argos Therapeutics Latest Developments
13.7 In-Cell-Art
13.7.1 In-Cell-Art Company Information
13.7.2 In-Cell-Art mRNA Vaccines Product Portfolios and Specifications
13.7.3 In-Cell-Art mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 In-Cell-Art Main Business Overview
13.7.5 In-Cell-Art Latest Developments
13.8 eTheRNA immunotherapies
13.8.1 eTheRNA immunotherapies Company Information
13.8.2 eTheRNA immunotherapies mRNA Vaccines Product Portfolios and Specifications
13.8.3 eTheRNA immunotherapies mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 eTheRNA immunotherapies Main Business Overview
13.8.5 eTheRNA immunotherapies Latest Developments
13.9 Ethris
13.9.1 Ethris Company Information
13.9.2 Ethris mRNA Vaccines Product Portfolios and Specifications
13.9.3 Ethris mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Ethris Main Business Overview
13.9.5 Ethris Latest Developments
13.10 Tiba Biotechnology
13.10.1 Tiba Biotechnology Company Information
13.10.2 Tiba Biotechnology mRNA Vaccines Product Portfolios and Specifications
13.10.3 Tiba Biotechnology mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Tiba Biotechnology Main Business Overview
13.10.5 Tiba Biotechnology Latest Developments
13.11 Pfizer
13.11.1 Pfizer Company Information
13.11.2 Pfizer mRNA Vaccines Product Portfolios and Specifications
13.11.3 Pfizer mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Pfizer Main Business Overview
13.11.5 Pfizer Latest Developments
13.12 Arcturus Therapeutics
13.12.1 Arcturus Therapeutics Company Information
13.12.2 Arcturus Therapeutics mRNA Vaccines Product Portfolios and Specifications
13.12.3 Arcturus Therapeutics mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Arcturus Therapeutics Main Business Overview
13.12.5 Arcturus Therapeutics Latest Developments
13.13 Genexine
13.13.1 Genexine Company Information
13.13.2 Genexine mRNA Vaccines Product Portfolios and Specifications
13.13.3 Genexine mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Genexine Main Business Overview
13.13.5 Genexine Latest Developments
13.14 Translate Bio
13.14.1 Translate Bio Company Information
13.14.2 Translate Bio mRNA Vaccines Product Portfolios and Specifications
13.14.3 Translate Bio mRNA Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Translate Bio Main Business Overview
13.14.5 Translate Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. mRNA Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. mRNA Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Conventional mRNA
Table 4. Major Players of Self-amplifying mRNA
Table 5. Major Players of Trans-amplifying mRNA
Table 6. Major Players of Circular mRNA
Table 7. Global mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 8. Global mRNA Vaccines Sales Market Share by Type (2021-2026)
Table 9. Global mRNA Vaccines Revenue by Type (2021-2026) & ($ million)
Table 10. Global mRNA Vaccines Revenue Market Share by Type (2021-2026)
Table 11. Global mRNA Vaccines Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Standard IVT Platform Vaccines
Table 13. Major Players of Modular Platform Vaccines
Table 14. Major Players of Lyophilized mRNA Vaccines
Table 15. Global mRNA Vaccines Sales by Platform Approach (2021-2026) & (K Dose)
Table 16. Global mRNA Vaccines Sales Market Share by Platform Approach (2021-2026)
Table 17. Global mRNA Vaccines Revenue by Platform Approach (2021-2026) & ($ million)
Table 18. Global mRNA Vaccines Revenue Market Share by Platform Approach (2021-2026)
Table 19. Global mRNA Vaccines Sale Price by Platform Approach (2021-2026) & (US$/Dose)
Table 20. Major Players of Single-antigen Vaccines
Table 21. Major Players of Multivalent Vaccines
Table 22. Major Players of Personalized Vaccines
Table 23. Global mRNA Vaccines Sales by Antigen Strategy (2021-2026) & (K Dose)
Table 24. Global mRNA Vaccines Sales Market Share by Antigen Strategy (2021-2026)
Table 25. Global mRNA Vaccines Revenue by Antigen Strategy (2021-2026) & ($ million)
Table 26. Global mRNA Vaccines Revenue Market Share by Antigen Strategy (2021-2026)
Table 27. Global mRNA Vaccines Sale Price by Antigen Strategy (2021-2026) & (US$/Dose)
Table 28. Global mRNA Vaccines Sale by Application (2021-2026) & (K Dose)
Table 29. Global mRNA Vaccines Sale Market Share by Application (2021-2026)
Table 30. Global mRNA Vaccines Revenue by Application (2021-2026) & ($ million)
Table 31. Global mRNA Vaccines Revenue Market Share by Application (2021-2026)
Table 32. Global mRNA Vaccines Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global mRNA Vaccines Sales by Company (2021-2026) & (K Dose)
Table 34. Global mRNA Vaccines Sales Market Share by Company (2021-2026)
Table 35. Global mRNA Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 36. Global mRNA Vaccines Revenue Market Share by Company (2021-2026)
Table 37. Global mRNA Vaccines Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers mRNA Vaccines Producing Area Distribution and Sales Area
Table 39. Players mRNA Vaccines Products Offered
Table 40. mRNA Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global mRNA Vaccines Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global mRNA Vaccines Sales Market Share Geographic Region (2021-2026)
Table 45. Global mRNA Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global mRNA Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global mRNA Vaccines Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global mRNA Vaccines Sales Market Share by Country/Region (2021-2026)
Table 49. Global mRNA Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global mRNA Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas mRNA Vaccines Sales by Country (2021-2026) & (K Dose)
Table 52. Americas mRNA Vaccines Sales Market Share by Country (2021-2026)
Table 53. Americas mRNA Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 55. Americas mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 56. APAC mRNA Vaccines Sales by Region (2021-2026) & (K Dose)
Table 57. APAC mRNA Vaccines Sales Market Share by Region (2021-2026)
Table 58. APAC mRNA Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 60. APAC mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 61. Europe mRNA Vaccines Sales by Country (2021-2026) & (K Dose)
Table 62. Europe mRNA Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 64. Europe mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa mRNA Vaccines Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa mRNA Vaccines Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of mRNA Vaccines
Table 70. Key Market Challenges & Risks of mRNA Vaccines
Table 71. Key Industry Trends of mRNA Vaccines
Table 72. mRNA Vaccines Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. mRNA Vaccines Distributors List
Table 75. mRNA Vaccines Customer List
Table 76. Global mRNA Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global mRNA Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas mRNA Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas mRNA Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC mRNA Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC mRNA Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe mRNA Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe mRNA Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa mRNA Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa mRNA Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global mRNA Vaccines Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global mRNA Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global mRNA Vaccines Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global mRNA Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. Moderna Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 91. Moderna mRNA Vaccines Product Portfolios and Specifications
Table 92. Moderna mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. Moderna Main Business
Table 94. Moderna Latest Developments
Table 95. CureVac Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 96. CureVac mRNA Vaccines Product Portfolios and Specifications
Table 97. CureVac mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. CureVac Main Business
Table 99. CureVac Latest Developments
Table 100. Sanofi Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 101. Sanofi mRNA Vaccines Product Portfolios and Specifications
Table 102. Sanofi mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Sanofi Main Business
Table 104. Sanofi Latest Developments
Table 105. BioNTech Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 106. BioNTech mRNA Vaccines Product Portfolios and Specifications
Table 107. BioNTech mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. BioNTech Main Business
Table 109. BioNTech Latest Developments
Table 110. Sangamo Therapeutics Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 111. Sangamo Therapeutics mRNA Vaccines Product Portfolios and Specifications
Table 112. Sangamo Therapeutics mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Sangamo Therapeutics Main Business
Table 114. Sangamo Therapeutics Latest Developments
Table 115. Argos Therapeutics Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 116. Argos Therapeutics mRNA Vaccines Product Portfolios and Specifications
Table 117. Argos Therapeutics mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Argos Therapeutics Main Business
Table 119. Argos Therapeutics Latest Developments
Table 120. In-Cell-Art Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 121. In-Cell-Art mRNA Vaccines Product Portfolios and Specifications
Table 122. In-Cell-Art mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. In-Cell-Art Main Business
Table 124. In-Cell-Art Latest Developments
Table 125. eTheRNA immunotherapies Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 126. eTheRNA immunotherapies mRNA Vaccines Product Portfolios and Specifications
Table 127. eTheRNA immunotherapies mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. eTheRNA immunotherapies Main Business
Table 129. eTheRNA immunotherapies Latest Developments
Table 130. Ethris Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 131. Ethris mRNA Vaccines Product Portfolios and Specifications
Table 132. Ethris mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Ethris Main Business
Table 134. Ethris Latest Developments
Table 135. Tiba Biotechnology Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 136. Tiba Biotechnology mRNA Vaccines Product Portfolios and Specifications
Table 137. Tiba Biotechnology mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Tiba Biotechnology Main Business
Table 139. Tiba Biotechnology Latest Developments
Table 140. Pfizer Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 141. Pfizer mRNA Vaccines Product Portfolios and Specifications
Table 142. Pfizer mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. Pfizer Main Business
Table 144. Pfizer Latest Developments
Table 145. Arcturus Therapeutics Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 146. Arcturus Therapeutics mRNA Vaccines Product Portfolios and Specifications
Table 147. Arcturus Therapeutics mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. Arcturus Therapeutics Main Business
Table 149. Arcturus Therapeutics Latest Developments
Table 150. Genexine Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 151. Genexine mRNA Vaccines Product Portfolios and Specifications
Table 152. Genexine mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Genexine Main Business
Table 154. Genexine Latest Developments
Table 155. Translate Bio Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 156. Translate Bio mRNA Vaccines Product Portfolios and Specifications
Table 157. Translate Bio mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 158. Translate Bio Main Business
Table 159. Translate Bio Latest Developments
Table 1. mRNA Vaccines Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. mRNA Vaccines Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Conventional mRNA
Table 4. Major Players of Self-amplifying mRNA
Table 5. Major Players of Trans-amplifying mRNA
Table 6. Major Players of Circular mRNA
Table 7. Global mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 8. Global mRNA Vaccines Sales Market Share by Type (2021-2026)
Table 9. Global mRNA Vaccines Revenue by Type (2021-2026) & ($ million)
Table 10. Global mRNA Vaccines Revenue Market Share by Type (2021-2026)
Table 11. Global mRNA Vaccines Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Standard IVT Platform Vaccines
Table 13. Major Players of Modular Platform Vaccines
Table 14. Major Players of Lyophilized mRNA Vaccines
Table 15. Global mRNA Vaccines Sales by Platform Approach (2021-2026) & (K Dose)
Table 16. Global mRNA Vaccines Sales Market Share by Platform Approach (2021-2026)
Table 17. Global mRNA Vaccines Revenue by Platform Approach (2021-2026) & ($ million)
Table 18. Global mRNA Vaccines Revenue Market Share by Platform Approach (2021-2026)
Table 19. Global mRNA Vaccines Sale Price by Platform Approach (2021-2026) & (US$/Dose)
Table 20. Major Players of Single-antigen Vaccines
Table 21. Major Players of Multivalent Vaccines
Table 22. Major Players of Personalized Vaccines
Table 23. Global mRNA Vaccines Sales by Antigen Strategy (2021-2026) & (K Dose)
Table 24. Global mRNA Vaccines Sales Market Share by Antigen Strategy (2021-2026)
Table 25. Global mRNA Vaccines Revenue by Antigen Strategy (2021-2026) & ($ million)
Table 26. Global mRNA Vaccines Revenue Market Share by Antigen Strategy (2021-2026)
Table 27. Global mRNA Vaccines Sale Price by Antigen Strategy (2021-2026) & (US$/Dose)
Table 28. Global mRNA Vaccines Sale by Application (2021-2026) & (K Dose)
Table 29. Global mRNA Vaccines Sale Market Share by Application (2021-2026)
Table 30. Global mRNA Vaccines Revenue by Application (2021-2026) & ($ million)
Table 31. Global mRNA Vaccines Revenue Market Share by Application (2021-2026)
Table 32. Global mRNA Vaccines Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global mRNA Vaccines Sales by Company (2021-2026) & (K Dose)
Table 34. Global mRNA Vaccines Sales Market Share by Company (2021-2026)
Table 35. Global mRNA Vaccines Revenue by Company (2021-2026) & ($ millions)
Table 36. Global mRNA Vaccines Revenue Market Share by Company (2021-2026)
Table 37. Global mRNA Vaccines Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers mRNA Vaccines Producing Area Distribution and Sales Area
Table 39. Players mRNA Vaccines Products Offered
Table 40. mRNA Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global mRNA Vaccines Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global mRNA Vaccines Sales Market Share Geographic Region (2021-2026)
Table 45. Global mRNA Vaccines Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global mRNA Vaccines Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global mRNA Vaccines Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global mRNA Vaccines Sales Market Share by Country/Region (2021-2026)
Table 49. Global mRNA Vaccines Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global mRNA Vaccines Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas mRNA Vaccines Sales by Country (2021-2026) & (K Dose)
Table 52. Americas mRNA Vaccines Sales Market Share by Country (2021-2026)
Table 53. Americas mRNA Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 55. Americas mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 56. APAC mRNA Vaccines Sales by Region (2021-2026) & (K Dose)
Table 57. APAC mRNA Vaccines Sales Market Share by Region (2021-2026)
Table 58. APAC mRNA Vaccines Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 60. APAC mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 61. Europe mRNA Vaccines Sales by Country (2021-2026) & (K Dose)
Table 62. Europe mRNA Vaccines Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 64. Europe mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa mRNA Vaccines Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa mRNA Vaccines Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa mRNA Vaccines Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa mRNA Vaccines Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of mRNA Vaccines
Table 70. Key Market Challenges & Risks of mRNA Vaccines
Table 71. Key Industry Trends of mRNA Vaccines
Table 72. mRNA Vaccines Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. mRNA Vaccines Distributors List
Table 75. mRNA Vaccines Customer List
Table 76. Global mRNA Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global mRNA Vaccines Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas mRNA Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas mRNA Vaccines Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC mRNA Vaccines Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC mRNA Vaccines Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe mRNA Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe mRNA Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa mRNA Vaccines Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa mRNA Vaccines Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global mRNA Vaccines Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global mRNA Vaccines Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global mRNA Vaccines Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global mRNA Vaccines Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. Moderna Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 91. Moderna mRNA Vaccines Product Portfolios and Specifications
Table 92. Moderna mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. Moderna Main Business
Table 94. Moderna Latest Developments
Table 95. CureVac Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 96. CureVac mRNA Vaccines Product Portfolios and Specifications
Table 97. CureVac mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. CureVac Main Business
Table 99. CureVac Latest Developments
Table 100. Sanofi Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 101. Sanofi mRNA Vaccines Product Portfolios and Specifications
Table 102. Sanofi mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. Sanofi Main Business
Table 104. Sanofi Latest Developments
Table 105. BioNTech Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 106. BioNTech mRNA Vaccines Product Portfolios and Specifications
Table 107. BioNTech mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. BioNTech Main Business
Table 109. BioNTech Latest Developments
Table 110. Sangamo Therapeutics Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 111. Sangamo Therapeutics mRNA Vaccines Product Portfolios and Specifications
Table 112. Sangamo Therapeutics mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Sangamo Therapeutics Main Business
Table 114. Sangamo Therapeutics Latest Developments
Table 115. Argos Therapeutics Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 116. Argos Therapeutics mRNA Vaccines Product Portfolios and Specifications
Table 117. Argos Therapeutics mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Argos Therapeutics Main Business
Table 119. Argos Therapeutics Latest Developments
Table 120. In-Cell-Art Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 121. In-Cell-Art mRNA Vaccines Product Portfolios and Specifications
Table 122. In-Cell-Art mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. In-Cell-Art Main Business
Table 124. In-Cell-Art Latest Developments
Table 125. eTheRNA immunotherapies Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 126. eTheRNA immunotherapies mRNA Vaccines Product Portfolios and Specifications
Table 127. eTheRNA immunotherapies mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. eTheRNA immunotherapies Main Business
Table 129. eTheRNA immunotherapies Latest Developments
Table 130. Ethris Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 131. Ethris mRNA Vaccines Product Portfolios and Specifications
Table 132. Ethris mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Ethris Main Business
Table 134. Ethris Latest Developments
Table 135. Tiba Biotechnology Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 136. Tiba Biotechnology mRNA Vaccines Product Portfolios and Specifications
Table 137. Tiba Biotechnology mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Tiba Biotechnology Main Business
Table 139. Tiba Biotechnology Latest Developments
Table 140. Pfizer Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 141. Pfizer mRNA Vaccines Product Portfolios and Specifications
Table 142. Pfizer mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. Pfizer Main Business
Table 144. Pfizer Latest Developments
Table 145. Arcturus Therapeutics Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 146. Arcturus Therapeutics mRNA Vaccines Product Portfolios and Specifications
Table 147. Arcturus Therapeutics mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. Arcturus Therapeutics Main Business
Table 149. Arcturus Therapeutics Latest Developments
Table 150. Genexine Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 151. Genexine mRNA Vaccines Product Portfolios and Specifications
Table 152. Genexine mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Genexine Main Business
Table 154. Genexine Latest Developments
Table 155. Translate Bio Basic Information, mRNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 156. Translate Bio mRNA Vaccines Product Portfolios and Specifications
Table 157. Translate Bio mRNA Vaccines Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 158. Translate Bio Main Business
Table 159. Translate Bio Latest Developments
LIST OF FIGURES
Figure 1. Picture of mRNA Vaccines
Figure 2. mRNA Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global mRNA Vaccines Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global mRNA Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. mRNA Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. mRNA Vaccines Sales Market Share by Country/Region (2025)
Figure 10. mRNA Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Conventional mRNA
Figure 12. Product Picture of Self-amplifying mRNA
Figure 13. Product Picture of Trans-amplifying mRNA
Figure 14. Product Picture of Circular mRNA
Figure 15. Global mRNA Vaccines Sales Market Share by Type in 2026
Figure 16. Global mRNA Vaccines Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Standard IVT Platform Vaccines
Figure 18. Product Picture of Modular Platform Vaccines
Figure 19. Product Picture of Lyophilized mRNA Vaccines
Figure 20. Global mRNA Vaccines Sales Market Share by Platform Approach in 2026
Figure 21. Global mRNA Vaccines Revenue Market Share by Platform Approach (2021-2026)
Figure 22. Product Picture of Single-antigen Vaccines
Figure 23. Product Picture of Multivalent Vaccines
Figure 24. Product Picture of Personalized Vaccines
Figure 25. Global mRNA Vaccines Sales Market Share by Antigen Strategy in 2026
Figure 26. Global mRNA Vaccines Revenue Market Share by Antigen Strategy (2021-2026)
Figure 27. mRNA Vaccines Consumed in Infectious Diseases
Figure 28. Global mRNA Vaccines Market: Infectious Diseases (2021-2026) & (K Dose)
Figure 29. mRNA Vaccines Consumed in Autoimmune Diseases
Figure 30. Global mRNA Vaccines Market: Autoimmune Diseases (2021-2026) & (K Dose)
Figure 31. mRNA Vaccines Consumed in Cancers
Figure 32. Global mRNA Vaccines Market: Cancers (2021-2026) & (K Dose)
Figure 33. mRNA Vaccines Consumed in Others
Figure 34. Global mRNA Vaccines Market: Others (2021-2026) & (K Dose)
Figure 35. Global mRNA Vaccines Sale Market Share by Application (2025)
Figure 36. Global mRNA Vaccines Revenue Market Share by Application in 2025
Figure 37. mRNA Vaccines Sales by Company in 2025 (K Dose)
Figure 38. Global mRNA Vaccines Sales Market Share by Company in 2025
Figure 39. mRNA Vaccines Revenue by Company in 2025 ($ millions)
Figure 40. Global mRNA Vaccines Revenue Market Share by Company in 2025
Figure 41. Global mRNA Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global mRNA Vaccines Revenue Market Share by Geographic Region in 2025
Figure 43. Americas mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 44. Americas mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 45. APAC mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 46. APAC mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 47. Europe mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 48. Europe mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 50. Middle East & Africa mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 51. Americas mRNA Vaccines Sales Market Share by Country in 2025
Figure 52. Americas mRNA Vaccines Revenue Market Share by Country (2021-2026)
Figure 53. Americas mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 54. Americas mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 55. United States mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC mRNA Vaccines Sales Market Share by Region in 2025
Figure 60. APAC mRNA Vaccines Revenue Market Share by Region (2021-2026)
Figure 61. APAC mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 62. APAC mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 63. China mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 67. India mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe mRNA Vaccines Sales Market Share by Country in 2025
Figure 71. Europe mRNA Vaccines Revenue Market Share by Country (2021-2026)
Figure 72. Europe mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 73. Europe mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 74. Germany mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 75. France mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 76. UK mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa mRNA Vaccines Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 82. Egypt mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of mRNA Vaccines in 2026
Figure 88. Manufacturing Process Analysis of mRNA Vaccines
Figure 89. Industry Chain Structure of mRNA Vaccines
Figure 90. Channels of Distribution
Figure 91. Global mRNA Vaccines Sales Market Forecast by Region (2027-2032)
Figure 92. Global mRNA Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global mRNA Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global mRNA Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 95. Global mRNA Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 96. Global mRNA Vaccines Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of mRNA Vaccines
Figure 2. mRNA Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global mRNA Vaccines Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global mRNA Vaccines Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. mRNA Vaccines Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. mRNA Vaccines Sales Market Share by Country/Region (2025)
Figure 10. mRNA Vaccines Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Conventional mRNA
Figure 12. Product Picture of Self-amplifying mRNA
Figure 13. Product Picture of Trans-amplifying mRNA
Figure 14. Product Picture of Circular mRNA
Figure 15. Global mRNA Vaccines Sales Market Share by Type in 2026
Figure 16. Global mRNA Vaccines Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Standard IVT Platform Vaccines
Figure 18. Product Picture of Modular Platform Vaccines
Figure 19. Product Picture of Lyophilized mRNA Vaccines
Figure 20. Global mRNA Vaccines Sales Market Share by Platform Approach in 2026
Figure 21. Global mRNA Vaccines Revenue Market Share by Platform Approach (2021-2026)
Figure 22. Product Picture of Single-antigen Vaccines
Figure 23. Product Picture of Multivalent Vaccines
Figure 24. Product Picture of Personalized Vaccines
Figure 25. Global mRNA Vaccines Sales Market Share by Antigen Strategy in 2026
Figure 26. Global mRNA Vaccines Revenue Market Share by Antigen Strategy (2021-2026)
Figure 27. mRNA Vaccines Consumed in Infectious Diseases
Figure 28. Global mRNA Vaccines Market: Infectious Diseases (2021-2026) & (K Dose)
Figure 29. mRNA Vaccines Consumed in Autoimmune Diseases
Figure 30. Global mRNA Vaccines Market: Autoimmune Diseases (2021-2026) & (K Dose)
Figure 31. mRNA Vaccines Consumed in Cancers
Figure 32. Global mRNA Vaccines Market: Cancers (2021-2026) & (K Dose)
Figure 33. mRNA Vaccines Consumed in Others
Figure 34. Global mRNA Vaccines Market: Others (2021-2026) & (K Dose)
Figure 35. Global mRNA Vaccines Sale Market Share by Application (2025)
Figure 36. Global mRNA Vaccines Revenue Market Share by Application in 2025
Figure 37. mRNA Vaccines Sales by Company in 2025 (K Dose)
Figure 38. Global mRNA Vaccines Sales Market Share by Company in 2025
Figure 39. mRNA Vaccines Revenue by Company in 2025 ($ millions)
Figure 40. Global mRNA Vaccines Revenue Market Share by Company in 2025
Figure 41. Global mRNA Vaccines Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global mRNA Vaccines Revenue Market Share by Geographic Region in 2025
Figure 43. Americas mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 44. Americas mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 45. APAC mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 46. APAC mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 47. Europe mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 48. Europe mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa mRNA Vaccines Sales 2021-2026 (K Dose)
Figure 50. Middle East & Africa mRNA Vaccines Revenue 2021-2026 ($ millions)
Figure 51. Americas mRNA Vaccines Sales Market Share by Country in 2025
Figure 52. Americas mRNA Vaccines Revenue Market Share by Country (2021-2026)
Figure 53. Americas mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 54. Americas mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 55. United States mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC mRNA Vaccines Sales Market Share by Region in 2025
Figure 60. APAC mRNA Vaccines Revenue Market Share by Region (2021-2026)
Figure 61. APAC mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 62. APAC mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 63. China mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 67. India mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe mRNA Vaccines Sales Market Share by Country in 2025
Figure 71. Europe mRNA Vaccines Revenue Market Share by Country (2021-2026)
Figure 72. Europe mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 73. Europe mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 74. Germany mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 75. France mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 76. UK mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa mRNA Vaccines Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa mRNA Vaccines Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa mRNA Vaccines Sales Market Share by Application (2021-2026)
Figure 82. Egypt mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries mRNA Vaccines Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of mRNA Vaccines in 2026
Figure 88. Manufacturing Process Analysis of mRNA Vaccines
Figure 89. Industry Chain Structure of mRNA Vaccines
Figure 90. Channels of Distribution
Figure 91. Global mRNA Vaccines Sales Market Forecast by Region (2027-2032)
Figure 92. Global mRNA Vaccines Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global mRNA Vaccines Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global mRNA Vaccines Revenue Market Share Forecast by Type (2027-2032)
Figure 95. Global mRNA Vaccines Sales Market Share Forecast by Application (2027-2032)
Figure 96. Global mRNA Vaccines Revenue Market Share Forecast by Application (2027-2032)
